Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

36

Revenue 2017

Xtandi

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Xtandi was produced by Astellas.

Pfizer hits accelerator on Xtandi trial in early prostate cancer

Pfizer hits accelerator on Xtandi trial in early prostate cancer failure. Both studies have been billed as having the potential to drive uptake of J&J's drug, adding pressure on Xtandi. ... And Pfizer and Astellas' position was further weakened by another trial called PLATO, which showed that adding Xtandi to Zytiga

Practice-changing data for J&J's Zytiga in prostate cancer

Practice-changing data for J&J's Zytiga in prostate cancer Astellas' fast-growing Xtandi (enzalutamide) which already has a pre-chemotherapy indication.

Astellas agrees €800m deal to buy Belgian biotech Ogeda

Astellas agrees €800m deal to buy Belgian biotech Ogeda prostate cancer therapy Xtandi (enzalutamide).

Can NICE deliver on its funding promises?

Can NICE deliver on its funding promises? What started with a positive recommendation last January for Astellas’ Xtandi in prostate cancer has certainly provided much work for the industry too.

Pfizer mulling product sale to streamline ops; sources

Pfizer mulling product sale to streamline ops; sources The Medivation deal brought in prostate cancer treatment Xtandi (enzalutamide), while buying Anacor gave the drugmaker a late-stage eczema candidate - crisaborole - tipped as a future blockbuster.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics